Study of Adiponectin Promotor Methylation status in patients with Non Alcoholic Fatty Liver Disease

Abd El-moaty, M.A.; Elsayed, I.A.; Saad, Y.; Eliwa, S.K.; Abd El-Maksoud, N.E.

doi:10.21608/bjas.2021.199032

	Study of Adiponectin Promotor Methylation status in patients with Non Alcoholic Fatty Liver Disease
Benha Journal of Applied Sciences
Article 17, Volume 6, Issue 5, September 2021, Page 105-107 PDF (344.21 K)
Document Type: Original Research Papers
DOI: 10.21608/bjas.2021.199032
View on SCiNiTO
Authors
M.A. Abd El-moaty¹; I.A. Elsayed¹; Y. Saad²; S.K. Eliwa¹; N.E. Abd El-Maksoud¹
¹Medical Biochemistry,Molecular Biology,Dept.,Faculty of Medicine, Benha Univ., Benha, Egypt
²Endemic Medicine , hepatogastroenterology, Dept., Faculty of Medicine, cairoUniv., cairo, Egypt
Abstract
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of liver disease globally, and it is likely to overtake alcoholic liver disease as the primary cause of end-stage liver disease in the coming decades. It affects both adults and children. In light of the significant hurdles in the prevention and control of NAFLD, recent research have shown that detecting adiponectin promotor methylation may be useful in NAFLD diagnosis, prognosis, and treatment.. Adiponectin (an adipose tissue hormone) induces apoptosis in hepatocytes, which has an anti-steatotic effect. Several samples from patients with NAFLD have been shown to exhibit adiponectin promotor methylation (NAFLD) so it can be used as non- invasive tool for NAFLD diagnosis.
Keywords
Non Alcoholic Fatty Liver Disease; Adiponectin; Methylation


Statistics Article View: 85 PDF Download: 277